PRASCEND (pergolide tablets) is the #1 treatment approved by the FDA for Pituitary Pars Intermedia Dysfunction (PPID).⁴ Proven to improve clinical signs such as delayed shedding, muscle wasting, and abnormal sweating. PRASCEND helps horses with PPID have healthier, more comfortable lives. PRASCEND is a rectangular light red colored, half-scored tablet containing 1 mg pergolide, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only.¹

What Its For

For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) in horses.

How It Works

When a horse has PPID, the pituitary gland overproduces hormones, making it difficult to keep bodily functions in a healthy working state, resulting in a variety of clinical signs. PRASCEND tablets act to curb the overproduction and secretion of these hormones to better control clinical signs.

Cautions/Precautions

Treatment with PRASCEND (pergolide tablets) may cause inappetence. The use of PRASCEND in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation. PRASCEND is approximately 90% associated with plasma proteins. Use caution if administering PRASCEND with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with PRASCEND (a dopamine agonist) since these agents may diminish the effectiveness of PRASCEND tablets. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Not for use in horses intended for human consumption. Do not crush tablets due to the potential for increased human exposure.

How It Works

Store at or below 25°C (77°F).

Active Ingredients

Pergolide, as pergolide mesylate

How Its Sold

PRASCEND (pergolide tablets) are available in 1 mg strength - packaged 10 tablets per blister and 60 or 160 tablets per carton.

References

1. Boehringer Ingelheim Vetmedica, Inc. PRASCEND (pergolide mesylate) Tablets for Horses: Freedom of Information Summary. NADA 141-331. US Food and Drug Administration. Sept 7, 2011.
2. Schott HC, Strachota JR, Marteniuk JV, Refsal KR. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide. J Vet Intern Med. 2025;39:e70109. doi:10.1111/jvim.70109
3. Stanley SD, DiMaio Knych H. Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate. In: Proc 56th Annu Conv Am Assoc Equine Pract. 2010:274-276.
4. Boehringer Ingelheim. Data Supporting PRASCEND as #1 treatment for PPID. Supporting Document VV-55869. November 2025.
PRASCEND is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0392-2025